Key facts
- Cellebrain’s last known valuation is $21.8M.
- It has raised $3.6M; the latest was Later Stage VC ($3.6M) in Dec 2024.
- Notable investors include SJ Investment Partners, Kolon Investment, BSK Investment, Laguna Investment, TimeWorks Investment.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Cellebrain
- ·The full record, as it builds
Funding rounds
No funding rounds for Cellebrain are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Cellebrain
Developer of a stem cell-based gene therapy platform designed to treat neurological disorders. The company's platform develops drugs based on a pipeline of stem cell-based gene therapy candidates that use mesenchymal stem cells as mediators to deliver therapeutic genes, enabling patients suffering from chronic stroke to get therapy.
- Sector
- Healthcare
- HQ
- Jeongeup-si, South Korea
- Founded
- 2018
- Employees
- 9
- Website
- cellebrain.com/
- Ownership
- Privately Held (backing)
Cellebrain doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Cellebrain shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Cellebrain in its N-PORT filings yet. We sweep new filings monthly.